PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Stopping Anticoagulation at Nursing Home Entry: No Stroke Signal, Higher Mortality

★ Editor's Pickanticoagulation discontinuationatrial fibrillationlong-term carenursing homeDOACwarfarinapixabanrivaroxabandabigatranedoxabanstroke preventionbleedingdeprescribingtarget trial emulationclone censor weightingMedicare claimsgeriatrics Anticoagulation / Hematology
Also in Geriatrics

Background Information

Does stopping anticoagulation increase mortality in atrial fibrillation?

Anticoagulation discontinuation in long-term care residents with atrial fibrillation has significant implications for stroke and bleeding management. Anticoagulation discontinuation did not increase stroke or bleeding risk but showed higher mortality (HR, 1.27; 95% CI, 1.23-1.31). Findings suggest stroke and bleeding risks remain stable after anticoagulation discontinuation; however, higher mortality requires consideration of individual patient factors. Anticoagulation discontinuation did not raise stroke or bleeding risks but increased mortality in long-term care residents with atrial fibrillation.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Kapoor A, Chen Z, Patel J, Ye Z, Lin H, Barnes G, Crawford S, Gurwitz JH

Citation: Kapoor A, Chen Z, Patel J, et al. Stroke and Bleeding Risk in Long-Term Care Residents With Atrial Fibrillation Who Discontinue Anticoagulation. JAMA network open. 2026;9(10):e2640964. doi:10.1001/jamanetworkopen.2026.40964

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.